JPMorgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Overweight rating and a price target of $9.00.

The analyst comments: “We are initiating coverage of Larimar Therapeutics (LRMR) with an Overweight rating and a Dec 2027 price target of $9. Larimar’s lead asset is nomlabofusp (nomla; CTI-1601), a subcutaneously administered, recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich’s ataxia (FA), a rare neurodegenerative disorder. In the near-term, in 2Q26, we expect to see topline results from the ongoing open-label (OL) study as well as feedback from the company’s type B meeting with the FDA to align on the overall BLA package readiness. The company expects a rolling BLA submission for accelerated approval (AA) in June 2026, pending FDA feedback, using skin FXN levels as a surrogate endpoint, with the final submission including the CMC module expected in 2H26; if approved, nomla would be the first FXN replacement therapy for FA, with a potential U.S. approval and launch in 1H27.”

For an analyst ratings summary and ratings history on Larimar Therapeutics click here. For more ratings news on Larimar Therapeutics click here.

Shares of Larimar Therapeutics closed at $3.47 yesterday.